Clinical trials: HIV-facial Lipoatrophy
HIV-facial Lipoatrophy
Artefill for the Treatment of HIV-associated Facial Lipoatrophy
Artefill is an injectable facial filler device that is currently approved by the FDA for the correction of nasolabial folds. This study seeks to examine the use of Artefill in the treatment of HIV associated facial lipoatrophy.
- Trial name
- NCT02009462
- Testing
- Artefill dermal filler
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Gerald Pierone, Jr. M.D.
Facial Lipoatrophy
Facial Lipoatrophy Correction Experience With SCULPTRA ("FACES" Study)
5 year, open-label study to evaluate safety of SCULPTRA on the signs of lipoatrophy of the face in at least 100 evaluable subjects with human immunodeficiency virus.
- Trial name
- FACES (NCT00360932)
- Testing
- SCULPTRA (poly-L-lactic acid injection)
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Bausch Health Americas, Inc.
HIV-Associated Lipodystrophy Syndrome
Psychological Morbidity and Facial Volume in HIV Lipodystrophy: Quantification of Treatment Outcome
The hypotheses of this study were that: 1. HIV lipodystrophy is associated with psychological morbidity relating to body image, anxiety and depression. 2.
- Trial name
- NCT01359917
- Volunteers
- 50 people
- Sponsor
- NHS Lothian
HIV Infection, Antiretroviral Side Effects
Polyacrylamide Hydrogel Injection in HIV-related Lipoatrophy
Combined antiretroviral therapy (cART) is associated with facial lipoatrophy, which is potentially stigmatizing for HIV-positive patients.
- Conditions
- HIV Infection, Antiretroviral Side Effects, Lipodystrophy Syndrome Related to HIV Infection
- Trial name
- LIPOPHILL (NCT01077765)
- Testing
- Eutrophill
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV Facial Lipoatrophy
Voluma Filler Agent For The Treatment of HIV-associated Facial Lipoatrophy
The purpose of this study is to test the safety of Voluma and see what effects it has on HIV facial lipoatrophy. The hypothesis is that Voluma will be safe, efficacious and positively impact the quality-of-life in the treatment…
- Trial name
- NCT02342223
- Testing
- Voluma
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jared Jagdeo, MD, MS
Human Immunodeficiency Virus, Facial Lipoatrophy
Safety, Efficacy and Psychological Effects of Treating Antiretroviral Drug-Induced Facial Lipoatrophy With Bio-Alcamid
Evaluate and record any changes in the Quality of Life and psychological state of the affected study group following treatment with Bio-Alcamid.
- Trial name
- NCT00333684
- Testing
- BIO-ALCAMID SOFT TISSUE ENDOPROSTHESIS
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Canadian Immunodeficiency Research Collaborative
HIV-Associated Lipodystrophy, HIV Infections
Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy
This is a multi-centre, open-label, 96 week study to evaluate the safety, tolerability and extent and duration of improvement in HIV-1 infected subjects with antiretroviral induced facial lipoatrophy, randomised in a 1:1 ratio to…
- Trial name
- NCT00126308
- Testing
- poly-L-lactic acid
- Where
- 18 sites in Australia
- Volunteers
- 100 people
- Sponsor
- Kirby Institute
HIV-Associated Lipodystrophy Syndrome
Safety and Efficacy of Intradermal Injections of Newfill Versus Eutrophill in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE
Treatment of facial lipoatrophy with dermal injections polylactic acid (Newfill TM) is a safe procedure and has been now widely used with a good efficacy.
- Trial name
- NCT00383734
- Testing
- Newfill, Eutrophill
- Where
- France
- Volunteers
- 148 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis